MedPage Today) — At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting “armored” CAR T-cell therapy that is designed to enhance persistence and antileukemic…
Read More
About The Author
